Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $2.1 million.

  • Monte Rosa Therapeutics' Depreciation & Amortization (CF) fell 38.04% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 531.04%. This contributed to the annual value of $8.1 million for FY2024, which is 3052.07% up from last year.
  • Monte Rosa Therapeutics' Depreciation & Amortization (CF) amounted to $2.1 million in Q3 2025, which was down 38.04% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Depreciation & Amortization (CF) ranged from a high of $2.1 million in Q2 2025 and a low of $1.2 million during Q1 2023
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $2.0 million (2025), whereas its average is $1.9 million.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first skyrocketed by 5833.33% in 2024, then plummeted by 38.04% in 2025.
  • Monte Rosa Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $1.8 million in 2023, then rose by 11.65% to $2.1 million in 2024, then rose by 1.65% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.1 million for Q2 2025, and $2.0 million during Q1 2025.